Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

J&J Topamax Successor Could Be Ready By 2009

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

J&J identifies RWJ-333369 as potential follow-on to Topamax, and plans to accelerate development ahead of expected topiramate generic entry in 2009. Phase IIb data will be available by end of 2005.

You may also be interested in...



J&J Anticipates Up To 14 NME Filings In 2006/2007

The company’s protease inhibitor TMC 114, which has a June 23 user fee date, will carry the brand name Prezista.

J&J Anticipates Up To 14 NME Filings In 2006/2007

The company’s protease inhibitor TMC 114, which has a June 23 user fee date, will carry the brand name Prezista.

J&J’s Topamax Cleared For Seizure Monotherapy

Johnson & Johnson subsidiary Ortho-McNeil's anti-convulsant Topamax (topiramate) cleared FDA June 29 for the supplemental indication of initial monotherapy for seizures

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency

See All
UsernamePublicRestriction

Register

PS062289

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By